Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Uterus and Cervix01:18

Uterus and Cervix

The uterus, commonly called the womb, is a vital reproductive organ in females designed to provide a nurturing environment for the implantation and growth of an embryo. It is shaped like a hollow pear and positioned between the urinary bladder and the rectum. The uterus's structure allows it to support and protect a developing fetus throughout pregnancy.
The uterus is securely anchored within the pelvic cavity by paired broad ligaments on either side. It is further stabilized by three pairs of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA.

The Journal of infectious diseases·2026
Same author

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

The lancet. HIV·2026
Same author

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.

Lancet (London, England)·2026
Same author

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial.

Lancet (London, England)·2026
Same author

Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.

The lancet. HIV·2024
Same journal

Obstetric Care for Patients With Cognitive Disabilities.

Clinical obstetrics and gynecology·2026
Same journal

Dissecting the Americans With Disabilities Act (ADA) Requirements when Approaching Obstetric Patients With Disabilities: How to Ensure Your Spaces are Accessible for All.

Clinical obstetrics and gynecology·2026
Same journal

Clinician Comfort and Barriers to the Obstetric and Gynecologic Care of Patients With Disabilities.

Clinical obstetrics and gynecology·2026
Same journal

Obstetric Care for Patients With Visual Impairments: Preconception Counseling Through Postpartum Care.

Clinical obstetrics and gynecology·2026
Same journal

Menstrual Management and Contraception for Patients With Disabilities.

Clinical obstetrics and gynecology·2026
Same journal

Favoring Elective Hospitalization in Pregnancies With Vasa Previa.

Clinical obstetrics and gynecology·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

External Cephalic Version: Is it an Effective and Safe Procedure?
08:49

External Cephalic Version: Is it an Effective and Safe Procedure?

Published on: June 6, 2020

Cervical dilation in second-trimester abortion.

Jennifer L Hayes1, Michelle C Fox

  • 1Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburg, PA 15213, USA. jhayes@mail.magee.edu

Clinical Obstetrics and Gynecology
|May 2, 2009
PubMed
Summary
This summary is machine-generated.

Second-trimester abortion via dilation and evacuation requires cervical preparation. Osmotic dilators like Dilapan-S and Lamicel offer faster dilation than laminaria, enabling same-day procedures.

More Related Videos

Laparoscopic Extracorporeal Knot-Tying for Uterine Vessel Occlusion during Hysterectomy with Cervical Cerclage in Large Uteri
05:21

Laparoscopic Extracorporeal Knot-Tying for Uterine Vessel Occlusion during Hysterectomy with Cervical Cerclage in Large Uteri

Published on: September 12, 2025

Continuous Telemetric In Utero Tracheal Pressure Measurements in Fetal Lambs
05:40

Continuous Telemetric In Utero Tracheal Pressure Measurements in Fetal Lambs

Published on: December 22, 2023

Related Experiment Videos

Last Updated: Jun 23, 2026

External Cephalic Version: Is it an Effective and Safe Procedure?
08:49

External Cephalic Version: Is it an Effective and Safe Procedure?

Published on: June 6, 2020

Laparoscopic Extracorporeal Knot-Tying for Uterine Vessel Occlusion during Hysterectomy with Cervical Cerclage in Large Uteri
05:21

Laparoscopic Extracorporeal Knot-Tying for Uterine Vessel Occlusion during Hysterectomy with Cervical Cerclage in Large Uteri

Published on: September 12, 2025

Continuous Telemetric In Utero Tracheal Pressure Measurements in Fetal Lambs
05:40

Continuous Telemetric In Utero Tracheal Pressure Measurements in Fetal Lambs

Published on: December 22, 2023

Area of Science:

  • Reproductive Health
  • Gynecology

Background:

  • Dilation and evacuation (D&E) is the most common second-trimester abortion method in the US.
  • Adequate cervical dilation is crucial to minimize risks like cervical laceration and uterine perforation.

Purpose of the Study:

  • To review methods for cervical preparation in second-trimester abortion.
  • To compare the efficacy and timing of different cervical dilators.

Main Methods:

  • Review of osmotic dilators (laminaria, Lamicel, Dilapan-S) and pharmacologic agents (misoprostol).
  • Analysis of dilation speed and procedural feasibility.

Main Results:

  • Dilapan-S and Lamicel provide faster maximum dilation compared to laminaria.
  • Faster dilation with Dilapan-S and Lamicel facilitates same-day D&E procedures.
  • Limited data exists for misoprostol's use in this context.

Conclusions:

  • Cervical preparation methods vary in dilation speed.
  • Clinician choice depends on factors like gestational age and preparation time.
  • Faster-acting dilators enhance procedural efficiency for second-trimester abortions.